Cerity Partners LLC Purchases 46,137 Shares of Zoetis Inc. $ZTS

Cerity Partners LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 14.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 371,198 shares of the company’s stock after purchasing an additional 46,137 shares during the quarter. Cerity Partners LLC owned about 0.08% of Zoetis worth $54,314,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Brighton Jones LLC raised its holdings in Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after acquiring an additional 2,978 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Zoetis in the first quarter valued at $1,916,000. Integrated Wealth Concepts LLC grew its position in shares of Zoetis by 13.3% in the first quarter. Integrated Wealth Concepts LLC now owns 7,553 shares of the company’s stock valued at $1,244,000 after purchasing an additional 888 shares in the last quarter. Caxton Associates LLP purchased a new stake in Zoetis during the 1st quarter worth about $930,000. Finally, MBB Public Markets I LLC purchased a new stake in Zoetis during the 1st quarter worth about $313,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Barclays assumed coverage on Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price for the company. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Stifel Nicolaus lowered their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday, November 18th. Weiss Ratings restated a “sell (d+)” rating on shares of Zoetis in a research report on Monday, December 29th. Finally, Morgan Stanley set a $160.00 price target on shares of Zoetis in a report on Thursday, December 18th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $160.18.

Zoetis Stock Performance

Zoetis stock opened at $125.82 on Thursday. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.40. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The stock has a market cap of $55.45 billion, a P/E ratio of 21.18, a price-to-earnings-growth ratio of 2.63 and a beta of 0.97. The firm’s fifty day moving average price is $123.97 and its 200-day moving average price is $141.03.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same quarter in the prior year, the firm earned $1.58 earnings per share. The firm’s revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Tuesday, January 20th. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio is presently 33.67%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.